20cm速递｜科创创新药ETF国泰（589720）涨超1.1%，政策优化与国际化转型驱动行业格局重塑

Group 1 - The pharmaceutical and chemical drug industry is undergoing policy deepening and globalization transformation, with a focus on drug and consumable procurement optimization, payment reform, and medical service price adjustments [1] - The pharmaceutical supply chain emphasizes innovation transformation and supply chain security, with optimism in the medical device sector regarding import substitution and the application of new technologies like AI [1] - China's pharmaceutical industry competitiveness is continuously enhancing due to demographic dividends, manufacturing advantages, and improved innovation capabilities, with a clear trend of innovative drugs and devices going global [1] Group 2 - The CXO industry is experiencing a turning point after adjustments, with a recovery in overseas orders and domestic innovative drug clinical progress, indicating a potential demand revival [1] - Small molecule drugs continue to dominate new drug research and development, with the outsourcing penetration rate expected to reach 65% by 2033 [1] - The industry is accelerating consolidation, with an increase in concentration among leading enterprises and gradual improvement in capacity utilization [1] Group 3 - The ETF tracking the innovative drug index focuses on high R&D investment and significant innovation achievements in the biopharmaceutical and chemical drug sectors, highlighting the research capabilities and long-term growth value of constituent companies [1]